— May 13, 2026

At the American Society of Gene & Cell Therapy (ASGCT) 2026 Presidential Symposium in Boston on May 13, 2026, Encoded Therapeutics reported one-year clinical results for ETX101, an experimental one-time gene therapy for Dravet syndrome — a severe childhood epilepsy caused by a single faulty gene. The headline is striking: after a single infusion, the children with the deepest response saw their seizures fall by roughly three-quarters and continued to gain developmental skills. It is early, small, and unblinded — but it is a clean example of what “precision medicine” is supposed to look like: fixing the specific molecular defect rather than blunting the symptom.

1. A One-Time Gene Therapy for a Genetic Epilepsy
2. Why Dravet Syndrome Is a Genetics Story
3. How ETX101 Works — Turning Up the Good Gene
4. The Numbers
5. What It Means
6. Honest Caveats
7. The Takeaway
Sources
Connections

1. A One-Time Gene Therapy for a Genetic Epilepsy

ETX101 is being tested in the POLARIS program — three open-label Phase 1/2 studies running in parallel: ENDEAVOR (United States), EXPEDITION (United Kingdom), and WAYFINDER (Australia). The data presented in May 2026 pooled 21 treated children, aged 6 months to 7 years, across four escalating dose levels. Each child received the therapy once, delivered by a single intracerebroventricular (ICV) injection — a neurosurgical route that places the medicine directly into the fluid-filled spaces of the brain. The goal is not to manage seizures day by day with pills, but to correct the underlying genetic shortfall with one procedure. That framing is the whole point of the story.

2. Why Dravet Syndrome Is a Genetics Story

Dravet syndrome is a developmental and epileptic encephalopathy that begins in the first year of life, usually with prolonged, often fever-triggered seizures in a previously healthy baby. It is treatment-resistant, carries an elevated risk of sudden unexpected death in epilepsy (SUDEP), and is accompanied by developmental slowing and, frequently, autism and movement problems.

In roughly 80–85% of cases, the cause is a single culprit: a de novo (new, non-inherited) loss-of-function mutation in SCN1A, the gene that encodes the Na_v1.1 sodium channel. Because one copy of the gene is broken, the brain makes only about half the normal amount of this channel — a state called haploinsufficiency. Na_v1.1 matters most in GABAergic inhibitory interneurons, the cells whose job is to quiet the brain down. Starve those brakes of their sodium channels and the network tips toward runaway excitation. This also explains a cruel clinical fact: common sodium-channel-blocking seizure drugs (carbamazepine, phenytoin, lamotrigine) tend to make Dravet worse, because they further silence the very cells that are already too quiet.

3. How ETX101 Works — Turning Up the Good Gene

Here is the clever part. SCN1A is too large to fit inside an AAV9 viral vector as a full replacement gene, so ETX101 does not add a new copy and does not edit DNA. Instead it is a gene-regulation therapy: the AAV9 vector delivers an engineered regulatory cassette that selectively boosts the child’s own remaining healthy SCN1A allele, and does so preferentially in the GABAergic interneurons where Na_v1.1 is needed. In effect, it turns up the volume on the good gene the patient still has, restoring more normal sodium-channel function to the brain’s inhibitory cells. Because it works through the body’s own transcription rather than cutting or rewriting the genome, it sidesteps some of the off-target and permanent-edit concerns that accompany CRISPR-style approaches — while carrying its own distinct set of unknowns.

4. The Numbers

The efficacy signal was dose-dependent. At dose level 3, the median reduction in convulsive seizure frequency was approximately 76%, sustained across 52 weeks of follow-up. On the developmental side, children assessed with the Vineland Adaptive Behavior Scales showed measurable gains in communication, motor function, and daily-living skills — and those treated before age two diverged early and durably from the developmental stagnation recorded in Encoded’s ENVISION natural-history study of untreated Dravet. On safety, the company reported no treatment- or procedure-related serious adverse events across all four dose levels; the most common finding was asymptomatic liver-enzyme (transaminase) elevation that resolved with standard management — a familiar, watch-list side effect of AAV gene therapies.

5. What It Means

For Dravet families, a durable 76% cut in seizures paired with developmental catch-up would be transformational, because the developmental damage — not just the seizures — is what shapes a child’s life. More broadly, ETX101 is a template. It shows that when a devastating disease is driven by one well-understood gene, you can sometimes design a therapy aimed squarely at that mechanism — here, restoring inhibition by upregulating SCN1A in the right cells — instead of reaching for blunt drugs that, in this disease, can backfire. That is the promise of genetics-guided, precision neurology: match the intervention to the molecular cause.

6. Honest Caveats

This is interim Phase 1/2 data, and the honest reading demands restraint:

Small and unblinded. Twenty-one children, spread across four dose levels, in open-label studies. The comparison is against a natural-history cohort (ENVISION), not a randomized placebo group — a reasonable but weaker benchmark that cannot fully rule out expectation effects or favorable selection.
The pivotal trial has not read out. The seizure-reduction figure comes from dose level 3, not from a controlled efficacy endpoint. The randomized, double-blind, sham-controlled ENDEAVOR Part 2 is the real test; enrollment is expected to finish by the end of 2026, with initial data anticipated in late 2027.
It is brain surgery. ICV delivery in an infant is an invasive, one-shot procedure under anesthesia, not a prescription.
Durability and long-term safety are unknown. Fifty-two weeks is encouraging, but Dravet is lifelong. Whether a single dose holds for years or decades — and whether any delayed effects emerge — simply is not yet known. AAV gene therapies require long-term monitoring.
Reduction is not freedom. A 76% median cut is not the same as stopping seizures, and group medians hide children who responded little.
Not approved, not available. ETX101 is investigational and accessible only through the trials.

7. The Takeaway

A one-time therapy that turns up a child’s own healthy SCN1A gene produced a durable ~76% median seizure reduction and early developmental gains in a first cohort of Dravet children — a genuinely encouraging proof of concept for precision genetic medicine in a single-gene brain disease. Treat it as a strong early signal, not a settled result. The number that will matter most is the randomized, sham-controlled readout expected in late 2027.

Sources

Primary Report (May 2026)

Encoded Therapeutics. New Clinical Data from POLARIS Phase 1/2 Trials of ETX101 Gene Therapy in Dravet Syndrome, ASGCT 2026 Presidential Symposium. Press release, May 13, 2026. BusinessWire
Encoded Therapeutics. To Present ETX101 Data in Dravet Syndrome at the 2026 ASGCT Presidential Symposium (presentation details; oral session Wednesday, May 13, 2026). encoded.com
CGTLive. ETX101 Gene Therapy Shows Early Developmental, Seizure Benefits in Dravet Syndrome. May 2026. cgtlive.com
Genetic Engineering & Biotechnology News (GEN). Gene Therapy ETX101 Improves Seizures and Neurodevelopment in Dravet Syndrome in Phase I/II. May 2026. genengnews.com
NeurologyLive. Gene Therapy ETX101 Demonstrates Significant Effects on Seizure Reduction, Neurodevelopmental Outcomes in POLARIS Phase 1/2 Program. May 2026. neurologylive.com
American Epilepsy Society. POLARIS Phase 1/2 Program: Interim Safety and Preliminary Efficacy Results of ETX101. Abstract. aesnet.org

Trial Registration & Background

ClinicalTrials.gov. ENDEAVOR: A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome. NCT05419492
ASGCT. 2026 Annual Meeting, Boston, May 11–15, 2026. annualmeeting.asgct.org
Claes L, Del-Favero J, Ceulemans B, Lagae L, Van Broeckhoven C, De Jonghe P. De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. Am J Hum Genet. 2001;68(6):1327–1332. doi:10.1086/320609 · PMID 11359211

PubMed Topic Searches

Connections

Back to Table of Contents